RARE Earnings Date: Nov 3, 2026 (Estimated) — Ultragenyx Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RARE's next earnings date?
Ultragenyx Pharmaceutical Inc. (RARE) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.10 on revenue of $182.5M.
How did RARE do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Ultragenyx Pharmaceutical Inc. posted EPS of -$0.90 versus the -$1.16 estimate, a beat of 22.4%. Revenue was $214.0M against a $182.5M estimate. The stock's 1-day post-earnings move was -3.4%.
How much does RARE stock move after earnings?
RARE beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -1.16 | -0.90 | +22.41% | $214.0M | ✅ Beat | -3.41% | +4.46% | +2.79% |
| 2026-05-05 | Q1 2026 | -1.48 | -1.84 | -24.32% | $136.0M | ❌ Miss | +3.68% | +7.32% | -6.80% |
| 2026-02-12 | Q4 2025 | -1.18 | -1.29 | -9.32% | $207.0M | ❌ Miss | -12.68% | -3.32% | -7.15% |
| 2025-11-04 | Q3 2025 | -1.22 | -1.81 | -48.36% | $159.9M | ❌ Miss | -1.82% | +2.43% | +12.57% |
| 2025-08-05 | Q2 2025 | -1.30 | -1.17 | +10.00% | $166.5M | ✅ Beat | -3.01% | -2.80% | +8.16% |
| 2025-02-13 | Q4 2024 | -1.27 | -1.39 | -9.45% | $164.9M | ❌ Miss | -2.37% | -2.14% | -8.92% |
| 2024-11-05 | Q3 2024 | -1.45 | -1.40 | +3.45% | $139.5M | ✅ Beat | -3.18% | -8.32% | -9.28% |
| 2024-08-01 | Q2 2024 | -1.72 | -1.52 | +11.63% | $147.0M | ✅ Beat | +14.31% | +13.91% | +28.61% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $214.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 52.3% | $112.0M | +38.6% | $71.9M | $91.5M | $80.8M | $95.0M |
| Royalty | 47.7% | $102.0M | +19.0% | $93.0M | $47.8M | $85.7M | $64.9M |
By region
Q2 FY26 · $214.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 56.5% | $121.0M | +17.6% | $117.0M | $57.8M | $102.9M | $83.5M |
| Latin America | 23.8% | $51.0M | +54.7% | $18.6M | $54.9M | $33.0M | $43.4M |
| EMEA | 16.4% | $35.0M | +32.6% | — | — | $26.4M | $27.9M |
| Asia Pacific | 3.3% | $7.0M | +66.7% | $3.6M | $3.3M | $4.2M | $5.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.